Smithers at WRIB: Advancing Large Molecule Bioanalytical Science

WRIB brings together pharmaceutical companies, contract research organizations, and global regulators to address current challenges in bioanalysis. The conference focuses on scientific and regulatory topics that directly impact drug development, with an emphasis on emerging modalities and evolving expectations.

WRIB serves as a forum for experienced bioanalytical scientists to exchange data, discuss assay challenges, and evaluate new technologies shaping the industry.

A Longstanding Commitment to WRIB

Smithers maintains a consistent presence at WRIB, with more than a decade of participation. The event remains a priority due to the exclusive focus of Smithers on large molecule bioanalytical services.

Attendance enables Smithers to stay aligned with current regulatory expectations and scientific developments while engaging directly with sponsors and industry peers. It also provides an opportunity to share technical expertise and collaborate on complex bioanalytical challenges.

Focus on Large Molecule Bioanalysis

Smithers specializes in large molecule bioanalysis, supporting programs that require high sensitivity and robust assay performance. This includes work across immunogenicity, pharmacokinetics, and biomarker analysis.

A core strength lies in addressing difficult assays. Many sponsors engage Smithers after encountering challenges with assay performance, particularly in anti-drug antibody (ADA) and immunogenicity testing. Smithers supports assay transfer, optimization, and validation to meet regulatory submission requirements.

Engagement with Regulatory Perspectives

WRIB provides direct access to regulatory agencies, including discussions that shape future bioanalytical guidance. While formal requirements may not shift immediately, ongoing dialogue informs how sponsors and CROs prepare data for submission.

Smithers uses these interactions to monitor regulatory direction and ensure alignment with evolving expectations. This includes considerations around assay performance, validation strategies, and data interpretation.

Evaluating New Technologies and Approaches

The conference environment allows for the evaluation of new technologies and methodologies being applied across the industry. Exposure to peer experiences and alternative approaches supports continuous improvement in assay development and execution.

Smithers assesses emerging tools to determine their applicability to client programs, with a focus on maintaining data quality and regulatory compliance.

Poster Presentation at WRIB

Smithers Associate Director, Anna Ilinskaya, will present a scientific poster titled “Fit-for-Purpose Evaluation of Simoa® Neuromarker Multiplex and Single Analyte Kits.” The presentation is scheduled for Tuesday, April 14th, at P07.

The poster highlights evaluation strategies for advanced biomarker platforms, reflecting ongoing efforts to support sensitive and reliable bioanalytical measurements.

Connect with Smithers at WRIB

Smithers will have a team of senior scientists, technical leaders, and executive leadership on-site to engage with sponsors. Discussions will cover both technical and operational aspects of bioanalytical programs, including assay development, troubleshooting, and timeline management.

Smithers emphasizes flexibility in meeting client objectives and maintains a network of industry relationships to support programs when additional capabilities are required.

Organizations developing large molecule therapeutics or facing bioanalytical challenges are encouraged to connect with Smithers during WRIB. Smithers urges attendees to schedule their meeting in advance to discuss specific program needs and explore strategies to advance development timelines with confidence